您的位置: 印度药房网 > 医药大数据 > 乳腺癌 >
Olaparib

Olaparib

【 药品别名 】 奥拉帕尼 Olaparib

【药品简介】 Olaparib是多聚二磷酸腺苷核糖聚合酶(PARP)抑制剂,用于治疗BRCA基因突变的肿瘤, 比如卵巢癌,乳腺癌,前列腺癌。PARP酶涉及细胞的正常功能,如DNA的转录和 DNA修复。美国药监局临床研究显示:奥拉帕尼无论是作为单药治疗或联合铂类为基础的化疗,均能够抑制试管中肿瘤细胞的生长,和减少人类肿瘤的生长。

【适应症状】 1)复发卵巢癌的维持治疗: ①对于上皮性复发性卵巢癌成人患者的维持治疗 ②对铂类敏感或部分敏感的输卵管或原发性腹膜癌的化疗。 2)接受3线或以上化疗方案后仍有进展的gBRCA基因突变的晚期卵巢癌。 3)BRCA基因突变的HER2阴性的转移性乳腺癌: ①曾接受新辅助化疗、辅助化疗、转移性化疗的有害或可疑有害的gBRCA基因突变、HER2阴性的转移性乳腺癌患者②激素受体阳性的患者需先进行内分泌治疗,不适合用内分泌治疗的患者再用奥拉帕尼。

印度Olaparib(奥拉帕尼 Olaparib)价格,正品图片,治疗乳腺癌药物, 购买Olaparib请到印度药房官方网站进行购买 【印度药房大全目录】

资料发布时间:2018-10-30 14:50:00 资料更新时间:2019-11-12 09:17:47

【印度Olaparib(奥拉帕尼 Olaparib)说明书】

【Olaparib用法用量】

推荐剂量:300mg,口服,每日两次,每天的总剂量为600mg。

服用方法:口服,饭前饭后均可。整片吞咽,不要咀嚼、压碎、溶解或分割药片

治疗时间:继续治疗直到疾病进展或不可接受的毒性。
 

【Olaparib不良反应】

最常见的奥拉帕尼不良反应(≥20%)是贫血,恶心,乏力,呕吐,腹泻,味觉障碍,消化不良,头痛,食欲下降,鼻咽炎/咽炎/URI,咳嗽,关节痛或肌肉骨骼痛,肌痛,背部疼痛,皮炎或皮疹和腹痛或不适。

最常见的奥拉帕尼实验室检查异常(≥25%)为提高肌酐,平均红细胞体积升高,降低血红蛋白,降低淋巴细胞,减少中性粒细胞绝对计数,并减少血小板。
 

【Olaparib注意事项】

1)骨髓增生异常综合征或急性髓系白血病(MDS/AML)患者发生接触奥拉帕尼有些情况下是致命的,监测患者的血液学毒性。

2)肺炎:如果肺炎确认停止奥拉帕尼。

3)胚胎胎儿毒性:奥拉帕尼可引起胎儿危害。奉劝女性奥拉帕尼的潜在风险繁殖潜力的一个胎儿,避免怀孕。

Olaparib uses

Olaparib is used in the treatment of ovarian cancer.

How olaparib works

Olaparib is an anticancer medication. It works by stopping Poly-ADP-ribose polymerase (PARP) from working. PARP is a protein that helps cancer cells to repair themselves and continue to survive.

Common side effects of olaparib

Nausea, Vomiting, Decreased blood cells (red cells, white cells, and platelets), Abdominal pain, Dizziness, Weakness, Sore throat, Runny nose, Diarrhea, Joint pain, Muscle pain, Back pain, Headache, Constipation, Mouth sore, Respiratory tract infection, Taste change,

Loss of appetite, Indigestion, Heartburn
Olaparib

生物活性

产品描述

Olaparib is a small molecule inhibitor of PARP1/PARP2 (IC50: 5/1 nM) but is less effective against the PARP tankyrase-1 (IC50: 1.5 μM).

靶点活性

PARP1,5 nM (cell free)

PARP2,1 nM (cell free)

实验溶液

15% Captisol: 15 mg/mL

体外活性

Following the establishment of a growth-inhibition curve for MMS on SW620 cells, the addition of the PARP-1 inhibitor at nM concentrations dose-dependently increased the effectiveness of MMS. Olaparib (AZD2281) was applied to SW620 cell lysates at a similar concentration range and identified the IC50 for PARP-1 inhibition to be around 6 nM and the total ablation of PARP-1 activity to be at concentrations of 30-100 nM [1]. Concentrations of cisplatin capable of suppressing cell survival by 90% in the presence of 0, 1 or 3 μM AZD2281 were approximately 2.1, 1.5, and 1.2 μM in HSC-2 cells, 1.7, 1.4, and 0.98 μM in Ca9-22 cells, and 2.4, 1.5 and 1.3 μM in SAS cells, respectively. The combination of 1 μM cisplatin and 1 μM AZD2281 attenuated growth rates compared with single treatments of either cisplatin or AZD2281 [2]. The largest difference in drug sensitivity between BRCA2-deficient KB2P cells (IC50: 91 nmol/L) and BRCA2-proficient KP cells (IC50: 8,135 nmol/L) was observed for AZD2281 [3].

体内活性

Animals bearing SW620 xenografted tumors were treated with AZD2281 (10 mg/kg, po) in combination with TMZ (50 mg/kg, po) once daily for 5 consecutive days, after which the tumors were left to grow out. A considerable inhibition of tumor volumes as compared with that of the TMZ alone group was observed for the TMZ plus AZD2281 combinations [1]. Tumor volumes of control group mice increased during the experimental period. The tumor growth of cisplatin and AZD2281 (25 mg/kg/day, every three days for five treatments) groups significantly decreased compared to the control group, and that of combination group was further decreased [2]. Combination treatment of Calu-6 xenografts with olaparib and fractionated radiotherapy caused significant tumor regression relative to radiotherapy alone. Olaparib alone, when given as single or multiple daily doses, or in combination with fractionated radiotherapy, increased the perfusion of tumor blood vessels [4].

激酶实验

This assay determined the ability of test compounds to inhibit PARP-1 enzyme activity. The method that was used was as reported. We measured PARP-2 activity inhibition by using a variation of the PARP-1 assay in which PARP-2 protein (recombinant) was bound down by a PARP-2 specific antibody in a 96-well white-walled plate. PARP-2 activity was measured following 3H-NAD+ DNA additions. After washing, scintillant was added to measure 3 H-incorporated ribosylations. For tankyrase-1, an AlphaScreen assay was developed in which HIS-tagged recombinant TANK-1 protein was incubated with biotinylated NAD+ in a 384-well ProxiPlate assay. Alpha beads were added to bind the HIS and biotin tags to create a proximity signal, whereas the inhibition of TANK-1 activity was directly proportional to the loss of this signal. All experiments were repeated at least three times [1].

细胞实验

HSC-2, Ca9-22, and SAS oral carcinoma cells were seeded in 24-well plates at a density of 2 × 104 cells/well. After overnight incubation, the culture medium was replaced with fresh medium containing various concentrations of PARP inhibitor AZD228 or cisplatin. After 24 h of treatment, the number of viable cells was assessed using an MTT assay as reported previously. Briefly, one-tenth of the fluid volume of 5 mg/mL MTT in RPMI-1640 medium was added to each well, followed by incubation for 4 h at 37 °C. After incubation, the medium was carefully removed and an adequate volume of 0.1 N HCl in isopropanol was added to each well and the resultant formazan crystals was dissolved. Absorbance was determined at 570 nm by microplate reader in 96-well assay plates. All experiments were performed in triplicate [2].

细胞系: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D

动物实验

Once the tumor diameter had reached 7 mm, the mice were randomly assigned to the following groups: (a) control (200 μL saline); (b) cisplatin (2 mg/kg per body weight, dissolved in 200 μL sterilized water); (c) AZD2281 (25 mg/kg per body weight, dissolved in 200 μL sterilized water); or (d) combination (both cisplatin and AZD2281). The chemicals were administered intraperitoneally every three days, five times. Although AZD2281 is administered orally in the clinic, intraperitoneal injection was recommended by the manufacturer because of easier manipulation and the ethical constraints associated with oral gavage administration to mice. Tumor size and body weight were measured at the time of administration. The tumor volume was calculated using following equation. Tumor volume = verticality × width × height × 0.5236 Three days after the last administration, all surviving mice were sacrificed [2].

动物模型:Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.

化学信息

分子量

434.46

分子式

C24H23FN4O3

CAS

763113-22-0

溶解度

DMSO: 80 mg/mL (184.1 mM)

Ethanol: <1 mg/mL

Water: <1 mg/mL

( < 1 mg/ml refers to the product slightly soluble or insoluble )

储存条件

store at -80°C

备注

For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

配制溶液

  1 mg 5 mg 10 mg
1 mM 2.302 ml 11.509 ml 23.017 ml
5 mM 0.46 ml 2.302 ml 4.603 ml
10 mM 0.23 ml 1.151 ml 2.302 ml
50 mM 0.046 ml 0.23 ml 0.46 ml

参考文献
 
1. Menear KA, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008 Oct 23;51(20):6581-91.
2. Yasukawa M, et al. Synergetic Effects of PARP Inhibitor AZD2281 in Oral Squamous Cell Carcinoma in Vitro and in Vivo. Int J Mol Sci. 2016 Feb 24;17(3):272.
3. Evers B, et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res. 2008 Jun 15;14(12):3916-25.
4. Senra JM, et al. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.Mol Cancer Ther. 2011 Oct;10(10):1949-58.
注:本站Olaparib(奥拉帕尼 Olaparib)药品说明均来自于官方,请咨询您的治疗医生了解更多细节。如需药品请到正规印度药房进行购买
上一篇:帕博西尼 下一篇:赫赛汀
Olaparib相关药品
帕博西尼
帕博西尼

帕博西尼与来曲唑治疗绝经后妇女的雌激素受体(ER)阳性,人表皮生长因子受体2(HER2)阴性晚期乳腺癌,作为初始内分泌为基础的治疗...

Olaparib
Olaparib

1)复发卵巢癌的维持治疗: ①对于上皮性复发性卵巢癌成人患者的维持治疗 ②对铂类敏感或部分敏感的输卵管或原发性腹膜癌的化...

赫赛汀
赫赛汀

Hertraz适用于治疗HER2过表达的转移性乳腺癌和转移性胃癌。 1、Hertraz作为单一药物治疗已接受过1个或多个化疗方案的转移性乳腺癌。...

Everolimus
Everolimus

1) 雌激素受体阳性,her2阴性乳腺癌 依维莫司联合依西美坦,用于雌激素受体阳性,HER2阴性的绝经后妇女,并且用来曲唑或阿那曲...

拉帕替尼
拉帕替尼

乳腺癌:拉帕替尼用于联合卡培他滨治疗ErbB-2过度表达的,既往接受过包括蒽环类,紫杉醇,曲妥珠单抗(赫赛汀)治疗的晚期或转移性乳...

Olaparib资讯
使用拉帕替尼治疗乳腺癌需要注意这些
使用拉帕替尼治疗乳腺癌需要注意这些

拉帕替尼用于治疗晚期激素相关乳腺癌,与其他癌症药物治疗后进展或扩散。只有当肿瘤检测为人表皮生长因子受体2(HER2)蛋白阳...

奥拉帕尼能治疗哪些癌症
奥拉帕尼能治疗哪些癌症

在癌症药物中常常可以看到一种药同时适用于多种不同的病症,这对患者来说是一件好事。奥拉帕尼是卵巢癌患者比较熟悉的治疗药...

奥拉帕尼的用法
奥拉帕尼的用法

靶向抗癌药奥拉帕尼是一流的口服PARP抑制剂,并且是第一种靶向药物,可通过使用DNA损伤反应(DDR)途径缺陷(例如BRCA突变)优先...

奥拉帕尼的不良反应
奥拉帕尼的不良反应

奥拉帕尼目前已获FDA批准用于多种适应症。它初用于治疗患有复发性卵巢上皮,输卵管或原发性腹膜癌的成年患者...

Olaparib的适应症
Olaparib的适应症

我们知道奥拉帕尼Olaparib是治疗卵巢癌的靶向药物。Olaparib还能治疗其他癌症吗?...

Palbociclib,乳腺癌的治疗
Palbociclib,乳腺癌的治疗

帕博西尼适应症用于治疗乳腺癌,其他适应症正在进行临床试验(非小细胞肺癌、淋巴瘤、多发性骨髓瘤)。帕博西尼胶囊:帕博西尼...

乳腺癌靶向药
乳腺癌靶向药

乳腺癌是全世界女性癌症死亡的主要原因。对于乳腺癌的治疗,靶向药物越来越受到重视。无数乳腺癌患者期待更好的治疗。...

印度奥拉帕尼的用量
印度奥拉帕尼的用量

随着社会的发展,越来越多的压力和不健康的生活习惯使越来越多的人开始患上癌症,尤其是卵巢癌,而且由于疾病的早期发现比较...

奥拉帕尼为卵巢癌患者的带来希望
奥拉帕尼为卵巢癌患者的带来希望

卵巢癌是女性常见的恶性肿瘤之一,其中以上皮癌最多见,其次是恶性生殖细胞肿瘤。卵巢癌深居盆腔,体积小,缺乏典型症状,难...

印度奥拉帕尼的可及性
印度奥拉帕尼的可及性

奥拉帕尼是市场之上第一个口服ADP-核糖聚合酶(PARP)抑制剂,它可阻止DNA修缮。...

Olaparib视频
什么是白血病?
什么是白血病?

白血病是一类造血干细胞恶性克隆性疾病...

中医与免疫治疗有什么关系?
中医与免疫治疗有什么关系?

中医有一句话叫做正气存内邪不可干,正气就包括了阴阳的平衡,气血、脏腑功能的平衡...

宝宝得了白血病还有救吗?
宝宝得了白血病还有救吗?

宝宝得了白血病不光有救,也有可能完全治愈,...

儿童白血病如何治疗?
儿童白血病如何治疗?

儿童白血病的治疗原则为早期诊断、早期治疗,有间歇、交替用药的方式,并坚持长期的治疗,预防复发。...

药房目录大全

Pharmacy Catalogue